March 18 SessionRegistration opens March 1.
The selected study examines the potential of antiviral molecules to inhibit the replication of SARS-CoV-2 and reduce the overall inflammatory response to infection. Our presenter and panelists, with their diverse expertise, will lead an in-depth discussion of the findings and explore the role of broad-spectrum antiviral agents to suppress the inflammatory response as a means to control disease severity.
SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate
Authors: David Olagnier, Ensieh Farahani, Jacob Thyrsted, Julia Blay-Cadanet, Angela Herengt, Manja Idorn, Alon Hait, Bruno Hernaez, Alice Knudsen, Marie Beck Iversen, Mirjam Schilling, Sofie E. Jørgensen, Michelle Thomsen, Line S. Reinert, Michael Lappe, Huy-Dung Hoang, Victoria H. Gilchrist, Anne Louise Hansen, Rasmus Ottosen, Camilla G. Nielsen, Charlotte Møller, Demi van der Horst, Suraj Peri, Siddharth Balachandran, Jinrong Huang, Martin Jakobsen, Esben B. Svenningsen, Thomas B. Poulsen, Lydia Bartsch, Anne L. Thielke, Yonglun Luo, Tommy Alain, Jan Rehwinkel, Antonio Alcamí, John Hiscott, Trine H. Mogensen, Søren R. Paludan and Christian K. Holm.
Nature Communications 02 Oct 2020
This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).
University of California Irvine
Mark Heise, Ph.D.
The University of North Carolina at Chapel Hill
Matthew Frieman, Ph.D.
University of Maryland School of Medicine
Sabra Klein, Ph.D.
Johns Hopkins Bloomberg School of Public Health
Timothy Sheahan, Ph.D.
University of North Carolina at Chapel Hill's Gillings School of Global Public Health
April 15, 2021, 2 p.m. ET (registration will open April 1)
Missed a past session?
Recordings are available free to ASM members.